Jason Trubiano

Professor Jason Trubiano is Head of the Department of Infectious Diseases in the Melbourne Medical School at the University of Melbourne, appointed in June 2025 after serving as Deputy Head since 2023. He is an Infectious Diseases Physician, Director of Infectious Diseases and Immunology at Austin Health, NHMRC Emerging Leadership Level 2 (EL2) Fellow, and laboratory head of the Centre for Antibiotic Allergy and Research at Austin Health. Additionally, he co-leads the Drug Hypersensitivity Stream for the National Allergy Centre of Excellence and heads the Clinical Trials Support Unit at the Peter Doherty Institute for Infection and Immunity. Trubiano completed his Bachelor of Biomedicine in 2002, Bachelor of Medicine/Bachelor of Surgery (MBBS) in 2007, and PhD in 2018, all at the University of Melbourne. He is a Fellow of the Royal Australasian College of Physicians (FRACP) and Fellow of the American Academy of Allergy, Asthma & Immunology (FAAAAI). During the COVID-19 pandemic, he headed the COVID-19 Unit at Austin Health.

His research group investigates the effects of antibiotic allergy labels on patient outcomes and health services, alongside the epidemiology, immunopathogenesis, genomic predictors, and diagnostics for severe cutaneous adverse reactions (SCAR). Achievements include validating point-of-care penicillin allergy decision tools like PEN-FAST, now used in health interventions and multicenter trials, and launching a national penicillin allergy database through the National Antibiotic Allergy Network. The group leads the Australasian Registry of Severe Cutaneous Reactions (AUS-SCAR), a national biobank, and develops novel T-cell diagnostics in collaboration with Vanderbilt University. Key publications are 'Development and Validation of a Penicillin Allergy Clinical Decision Rule' (JAMA Internal Medicine, 2020), 'Antibiotic Allergy' (The Lancet, 2019), 'Impact of an Integrated Antibiotic Allergy Testing Program on Antimicrobial Stewardship: A Multicenter Evaluation' (Clinical Infectious Diseases, 2017), 'The Penicillin Allergy Delabelling Program: A Multicenter Whole-of-Hospital Health Services Intervention and Comparative Effectiveness Study' (Clinical Infectious Diseases, 2021), and 'Antimicrobial allergy "labels" drive inappropriate antimicrobial prescribing: lessons for stewardship' (Journal of Antimicrobial Chemotherapy, 2016). Supported by NHMRC EL2 funding, his work advances antimicrobial stewardship and drug allergy management.

Professional Email: trubianoj@unimelb.edu.au